205 related articles for article (PubMed ID: 38504071)
61. Optimization of perioperative approaches for advanced and late stages of gastric cancer: clinical proposal based on literature evidence, personal experience, and ongoing trials and research.
Beeharry MK; Zhang TQ; Liu WT; Gang ZZ
World J Surg Oncol; 2020 Mar; 18(1):51. PubMed ID: 32151257
[TBL] [Abstract][Full Text] [Related]
62. [Progress and prospects of international cancer drug clinical research on gastric cancer].
Liu J; Liu YP
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Feb; 23(2):196-200. PubMed ID: 32074802
[TBL] [Abstract][Full Text] [Related]
63. Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis.
Yu G; Yu W; Xu X; Ye B; Yao L
PLoS One; 2021; 16(6):e0252829. PubMed ID: 34086821
[TBL] [Abstract][Full Text] [Related]
64. Comparisons of perioperative and long-term outcomes of laparoscopic versus open gastrectomy for advanced gastric cancer after neoadjuvant therapy: an updated pooled analysis of eighteen studies.
Pang HY; Chen XF; Chen LH; Yan MH; Chen ZX; Sun H
Eur J Med Res; 2023 Jul; 28(1):224. PubMed ID: 37408041
[TBL] [Abstract][Full Text] [Related]
65. Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: A new era for anal preservation.
Wang Y; Shen L; Wan J; Zhang H; Wu R; Wang J; Wang Y; Xu Y; Cai S; Zhang Z; Xia F
Front Immunol; 2022; 13():1067036. PubMed ID: 36569918
[TBL] [Abstract][Full Text] [Related]
66. Can neoadjuvant chemoradiotherapy combined with immunotherapy benefit patients with microsatellite stable locally advanced rectal cancer? a pooled and integration analysis.
Yue Y; Cheng M; Xi X; Wang Q; Wei M; Zheng B
Front Oncol; 2023; 13():1280995. PubMed ID: 37869097
[TBL] [Abstract][Full Text] [Related]
67. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
[TBL] [Abstract][Full Text] [Related]
68. The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis.
He W; Wang C; Li C; Nie X; Li H; Li J; Zhao N; Chen H; Miao X; Han Y; Peng L; Leng X
Front Immunol; 2023; 14():1118902. PubMed ID: 36875107
[TBL] [Abstract][Full Text] [Related]
69. Case Report: Clinical application of continuous arterial infusion chemotherapy in neoadjuvant therapy for locally advanced gastric cancer.
Lin W; Huang Z; Du Z; Wang Y; Zuo T
Front Oncol; 2023; 13():1214599. PubMed ID: 37427136
[TBL] [Abstract][Full Text] [Related]
70. Development and validation of a nomogram to predict pathological complete response in patients with locally advanced gastric adenocarcinoma treated with neoadjuvant chemotherapy in combination with PD-1 antibodies.
Li L; Chen G; Chen EY; Strickland MR; Zhao W; Zhang J; Li Z
J Gastrointest Oncol; 2023 Dec; 14(6):2373-2383. PubMed ID: 38196541
[TBL] [Abstract][Full Text] [Related]
71. [Significance of neoadjuvant immunotherapy combined with chemotherapy in the treatment of larynx preservation in locally advanced hypopharyngeal squamous cell carcinoma].
Wu J; Hu G; Li M; Wang Z; Ma W; Wang X; Zhu J; Pan M; Zeng Q
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2023 Sep; 37(9):715-720;728. PubMed ID: 37830119
[No Abstract] [Full Text] [Related]
72. Neoadjuvant immunotherapy prior to surgery for mucosal head and neck squamous cell carcinoma: Systematic review.
Amin N; Maroun CA; El Asmar M; Alkhatib HH; Guller M; Herberg ME; Zhu G; Seiwert TY; Pardoll D; Eisele DW; Fakhry C; Gourin CG; Mandal R
Head Neck; 2022 Feb; 44(2):562-571. PubMed ID: 34825751
[TBL] [Abstract][Full Text] [Related]
73. [Current status and research progress of third-line treatment for patients with gastric cancer in China].
Qi CS; Cheng SY; Shen L
Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):983-988. PubMed ID: 33342152
[TBL] [Abstract][Full Text] [Related]
74. [Postoperative complications and their influence on the prognosis factors in gastric cancer patients receiving neoadjuvant treatment].
Wang TB; Mao QK; Zhang XJ; Zhou H; Guo CG; Chen YT; Zhao DB
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):160-166. PubMed ID: 33508922
[No Abstract] [Full Text] [Related]
75. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer.
Deng HY; Wang WP; Wang YC; Hu WP; Ni PZ; Lin YD; Chen LQ
Eur J Cardiothorac Surg; 2017 Mar; 51(3):421-431. PubMed ID: 27694253
[TBL] [Abstract][Full Text] [Related]
76. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
77. Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer: Where Are We at?
Yeh JH; Yeh YS; Tsai HL; Huang CW; Chang TK; Su WC; Wang JY
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740693
[TBL] [Abstract][Full Text] [Related]
78. Adjuvant therapy for locally advanced gastric cancer.
Aoyama T; Yoshikawa T
Surg Today; 2017 Nov; 47(11):1295-1302. PubMed ID: 28251375
[TBL] [Abstract][Full Text] [Related]
79. Application of immune checkpoint inhibitors in immunotherapy for gastric cancer.
Wu YX; Zhou XY; Wang JQ; Chen GM; Chen JX; Wang RC; Huang JQ; Chen JS
Immunotherapy; 2023 Feb; 15(2):101-115. PubMed ID: 36597704
[TBL] [Abstract][Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
